7A - Triad 1 and 2 - LaValle - XX-B - Nov12 - glvhealth.comglvhealth.com/LargeFiles/Mod 20b CD/6...
Transcript of 7A - Triad 1 and 2 - LaValle - XX-B - Nov12 - glvhealth.comglvhealth.com/LargeFiles/Mod 20b CD/6...
1
1
Triad 1 and Triad 2 Stacking James LaValle, R.Ph., CCN
The following potential conflict of interest relationships are germane to my presentation.
Equipment: NoneSpeakers Bureau: NoneStock Shareholder: None
Grant/Research Support: NoneConsultant: None
Employment: Integrative Health Resources
Status of FDA devices used for the material being presented: NA/Non‐Clinical
Status of off‐label use of devices, drugs or other materials that constitute the subject of this presentation: NA/Non‐Clinical
Triad 1 and Triad 2 Stacking
Complex Progression in Autoimmunity Induced by
TRIAD 1 and Triad 2 RelationshipsJames B. LaValle
2
Copyright © 2012 James B. LaValle, Integrative Health Resources, LLC. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever, stored in a retrieval system, or transmitted in any form, or by any means, electronic, mechanical, photocopying, recording or
otherwise, without prior permission of the author.
This material is provided for educational and informational purposes only to licensed health care professionals. This information is obtained from
sources believed to be reliable, but its accuracy cannot be guaranteed. Herbs and other natural substances are very powerful and can occasionally cause
dangerous allergic reactions in a small percentage of the population. Licensed health care professionals should rely on sound professional
judgment when recommending herbs and natural medicines to specific individuals. Individual use of herbs and natural medicines should be supervised by an appropriate health care professional. The use of any
specific product should always be in accordance with the manufacturer's directions.
3
THE INTESTINAL MICROBIOMECOMPOSITION LIES SQUARELY
IN THE INTERSECTION OF DEVELOPING ALLERGIC AND AUTOIMMUNE DISEASES
4
GIMicroflora
Factors Affecting our GI Microflora
5
How Does Our GI Microflora Affect Us?
ANTICARCINO-
GENIC
IMMUNERESPONSE
VITAMINS &MINERAL
ABSORPTION
DIGESTION&
GUT HEALTH
CHOLEST.ASSIM.
RECOVERYFROM
DIARRHEA
GIMICROFLORA
6
2
Causes of Leaky Gut (dysbiosis)
Destruction of beneficial flora
‐Antibiotics, Xenobiotics, Infections
Inflammation of the Mucosal Barrier
‐NSAIDS, PPI’s esomeprazole, excess EtOH, Meds, Toxins, Stress, Gluten
‐Yeast promoting promoting – Yeast is #1 pathogen in the bowel
– Sugar, processed food, lack of fiber in the diet, excessive carbohydrate
7
Chemicals influencing epithelial permeability
• Histmamine
• Leukotrienes
• TNFα
• Inerleukin 4
• Serotonin
• Mast cell proteases
• Platelet activating factor
8
Antigen‐Antibody Complexes >Enter vascular circulation >Attach to brain, thyroid, joints, lungs, etc.
9
Allergies
• Allergy is an over reaction of the immune system to NON-harmful antigens
• Children with allergies have different bowel flora than kids that don’t.
• Kids with allergies tend to have – higher prevalence of C. difficile and S. aureus
– less Bifidobacteria and Bacteroides
• Breastfeeding increases Bifidobacteria as it contains growth factor for Bifido
10
11
Chain of Events to Trigger Food Allergy• Toxins and allergic material into gut
• Mast cell stimulation
• Histamine response
• Swelling of gut lining/decreased digestion
• Incompetent lining
• Absorption of large molecule/circulation
• Trigger antibody response
• Food allergy
12
One Pathway to Acidosis of Connective Tissue
• Mast cell aggravation
• Histamine production and levels increase
• Increased HCI production in stomach
• Depletion of bicarbonate buffer of blood/ connective tissue
• Increased connective tissue acidosis
• Tissue acidification is beginning of many chronic diseases and pathologies
3
13
Acidosis
• Bone demineralization
• Supports anaerobic metabolism
• Reduces energy and increases free radical burden to Krebs cycle
• Best Tests: low intracellular K, Mg, Zn
• Urine ketones
Celiac - Definition
• Celiac disease is a chronic inflammatory erosion of GI villi secondary to gluten allergy
• Wheat, rye, and barley contain gluten
• Gluten is a plant “protein” molecule
• Gluten is a combination of gliadin & glutenin
• Gluten is difficult to digest so = inflammatory
• Genetically modified wheat - 50% more gluten
14
Gluten Sensitivity
• Gliadin (a gluten protein) has direct effects on small intestines– Increases permeability of endothelial cells, allowing
food proteins to enter– Proline content of grains in general, forms
prolamines, irritating to gut wall, hard to digest– Blocks protease enzymes so protein unable to be
digested– Binds chemoattractant receptor which causes an
increase in a factor that destroys tight junctions15
Celiac Disease
• Villous atrophy of the small bowel leads to inability to absorb nutrients - wasting
• Genetic predisposition of U.S. population– 30% HLA-DQ2 – are at risk for celiac
– 12% HLA-DQ8
– 57% Less destructive variants (Glut. Sens.)
– <1% HLA-DQ4/4
16
Why us? Why now?
• Genetically modified wheat– 50% more gluten than 10 years ago
• Eating more wheat/gluten as it is stuffed into many processed foods
• Immunologic challenges (stimulation) from air-water-food-vaccines-toxins-SUGAR
• Abuse of antacids, famotadine, omeprazole, esomeprazole, etc: can’t breakdown food
• Stress is high, weakens the immune system17
Historical Blunder
• Gluten sensitivity and allergy is an immune process producing Antibodies (in the stool)– IgA, endomysial, transglutaminase– Blood tests for these antibody’s horrible insensitive
• Blood tests are not reliably positive until disease is full blown and causing significant problems
• Need to look at stool tests and recommend wheat avoidance. – DASH diet recommends 8 grains per day (4 veggies)
18
4
Blood Tests for Celiacs Dz
• Intestinal villi erosion:
• Blood tests are not sensitive enough, the disease goes undetected until there is significant damage:– Early partial villous atrophy = 30% detection
– Significant erosion and loss of height = 70%
– Complete erosion, total loss of villi = 100%
19
Celiac - General Population
• 11% of symptom free population has + gliadinantibodies in the blood– Of these, 45% had measurable intestinal
dysfunction, leaky gut, poor absorption
– 0% had villous atrophy on biopsy, but some showed inflammatory changes
• 30% of this same population had + stool antibodies
20
Prior Diagnosis
• + gliadin Ab’s were found in the following:– Chronic diarrhea = 50%
– IBS (Irritable Bowel Syndr.) = 57%
– Crohns or Ulcerative Colitis = 60%
– Autoimmune disease of any kind = 77%
But only 11% of this group had +blood test21
Gluten Sensitivity vs Celiac Disease
• Celiac Disease(CD): Autoimmune enteropathytriggered by intake of gluten
• Gluten Sensitivity: have gluten intolerance and may have similar symptoms as (CD).
• Clinical picture less severe and typically will not have transglutaminase antibodies
22
Differences
Celiac Disease
• intestinal permeability
Gluten Sensitivity
• Not associated with Intestinal permeability
• permeability
• Claudin expression
• TLR2
• T Reg cells
• No changes in IL‐6, IL21
23
SJOGREN’S SYNDROME AND THE GUT
Gut and Autoimmunity
24
5
Sjogren’s Syndrome
•A chronic autoimmune disorder in which white blood ells attack moisture producing glands in the body. 9 out of 10 patients are women and symptoms usually occur after the age of 40 but can occur to either sex at any age.
• Hallmark symptoms are dry eyes and dry mouth, but other symptoms can include enlarged salivary glands, vaginal dryness, fatigue, fever, joint pain and swelling and dry skin/rashes.
25
Symptoms
• Common: dry eyes, dry mouth, burning tongue, cracking tongue, increased dental caries, trouble swallowing, vaginal dryness, chronic dry cough, joint pain, muscle pain, low grade fevers, fatigue, enlarged saliva glands, oral candidiasis
• Less common:Inflammation in lungs, can
cause bronchitis or pneumonia
Inflammation in kidneys and liver leading to decreased kidney function, and hepatitis or cirrhosis
Peripheral neuropathiesVasculitis (inflammation of
the blood vessels)Pancreatitis
26
Incidence and co‐morbidities
•2nd most common autoimmune disease affecting at least 4,000,000 Americans
• 50% occur as primary diagnoses
• 50% occur secondarily with other autoimmune disease such as rheumatoid arthritis, Lupus (SLE), Scleroderma, and Polymositis
• 30 ‐ 50% of rheumatoid arthritis patients, 30% of Lupus pts, 4‐5% of scleroderma pts have SS
27
Diagnostic Criteria
•Dry mouth• Poor salivary gland production• Dry eyes• Often antinuclear antibodies are present (80% test positive)• Positive rheumatoid factor, with or without rheumatoid symptoms• Often enlarged parotid salivary glands, usually in primary SS (75‐95%).
28
Diagnostic Tests
1. Schirmer’s test - measures tear production2. Rose-Bengal staining - determines inflammation
of the cornea3. Salivary gland flow rate - measures saliva
production with a special X-ray called sialogram4. Salivary gland or lip biopsy measure
inflammation of tissue and infiltration of white blood cells
5. Urine tests and blood tests to rule out any kidney and liver involvement
29
Other Labs•Elevated sedimentation rates (indicate inflammation)• Mild anemia• Low albumin• Mild leukopenia with elevated eosinophils
• Autoimmune antigens HLA‐B8 and HLA‐DW3 are often present
• SS‐A and SS‐B antibodies • Increases in all classes of immunoglobulins.
30
6
Other conditions commonly associated with Sjogren’s:
• Autoimmune Thyroiditis (Hashimoto’s)
• Gastroesophageal reflux disease (GERD)
•Raynaud’s Disease ‐ occurs in 20% of SS patients
•Gastrointestinal ‐ abdominal pain, nausea, diarrhea
31
Prostaglandins
• Lack of PGE 1 is key factor in Sjogren’s
• PGE 1 needed for:
• Lacrimal and salivary gland secretion
• Animal studies show severe atrophy of these gland in linoleic acid deficiency
32
Conventional Medical TreatmentConventional Medical Treatment• Salivary aids ‐ artificial saliva preparations
• Saliva stimulant drugs ‐ pilocarpine and cevimeline
• Eye drops ‐ artificial tears, eye lubricant ointments
• Cyclyosporin eye drop
• Hydroxychloroquine ‐ an antimalarial drug which is also used in autoimmune diseases. The mechanism of action for autoimmunity is not known.
• If complications are severe, immunosuppressive drugs may be used.
• Palliative treatment ‐ drinking lots of fluids, using humidifiers, sucking on lemon drops or glycerin swabs, avoiding use of fans and hairdryers, etc.
33
Functional Medical Evaluation
• Systems evaluation ‐ symptoms questionnaire
• Toxicity evaluation
• Gastrointestinal evaluation
• Nervous system evaluation
• Hormonal evaluation
34
Immune System Review
• Cellular Immunity ‐lymphycytes (small WBC), B cells, T cells and killer cells
• Large WBC = myeloid cells= eosinophils and basophils and phagocytes (monocytes and macrophages).
• Macrophages activate T cells.
• Neutrophils ‐ a type of phagocyte called granulocytes
• T cells ‐ help to coordinate the overall immune response, help the body remember non‐self antigens. Release cytokines.
• T cell receptors need major histocompatibility complexes (MHC) to recognize antigens
• CD4 T cells = helper cells ‐promote immune response
• CD8 T cells = suppressor cells ‐ suppress immune response
35
TH2 side secretesfactors whichstimulate theproduction ofB‐Cells
An overproduction ofTH2 factorsleads to autoimmuneand allergic conditions
TH1 side secretes factors which stimulate action of CytotoxicT‐cells and NK cells
Natural Killer Cellsdestroy virally infected cells
Cytotoxic T‐cellsidentify andkill infectedhost cells
B‐cells/antibodieskill bacteriaoutside healthycells
TH 1Helper Cell
TH 2Helper Cell
Secrete Secrete
NKCellsInnate
Immunity
CytotoxicT‐Cells
SuppressorCells
B‐CellsAntibodies
IL 2 INF‐� IL 4
IL 10IL 6
TNF
IgE
IgM
IgG
IgA
IgD
Cross Regulate andMaintain balance
THELPERCELLS
7
Arbitrary units
Age in years
0 0120 12060 60
NK activity
T ‐cells
B‐cells
IL‐1/6TNFa
IL2
Age in years
AGE‐RELATED TRENDSIN THE IMMUNE SYSTEM
37
Toxicity
StressIntestines
Environmental Toxicity
Heavy Metals and Organic Chemicals
• Provoked urine• Packed red blood cell• Fecal metal
• Hair analysis• Electrodermal screening (EDS)
Detoxification Evaluation • Glutathione
• Organic acid urine
• Clearance challenge tests
• Amino acid profiles
Infectious Organisms
– Polymerase Chain Evaluation
– Fecal analysis
– EDS
38
Toxicity
Intestines Implicated in autoimmune diseases
Also may explain many of the GI related symptoms of Sjogren’s
Intestinal Integrity
Leaky gut/Dysbiosis are key elements
•Lactulose/Mannitol test
•Food sensitivity and allergy testing
• Hydrogen Breath Test
39
Intestinal Integrity and Autoimmunity
• Intestinal permeability seems to precede disease
• Regulation of permeability depends on “tight junctions” which are filled with several protein strands
• Commensal flora positively influence tight junctions
• Cytokines, especially TNF affect mucosal barrier in IBD
• Loss of mucosal barriers is necessary for autoimmunity to develop
• Antigens, ie gliaden, stimulate opening of tight junctions, cytokine production, white blood cell infiltration, and continued increased intestinal permeability
*Fasano A, Shea‐Donohue. Mechanisms of Disease:the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases . www.nature.com/clinicalpractice;gasthep, Sept. 20005 2:9.
40
Stress
Adrenal
Pancreas
Evaluation:
• Serum cortisol/DHEA
• Salivary neurotransmitter panels
• Urinary neurotransmitter panels
• Blood Test
CRP, Fibrinogen, Uric Acid, Insulin,
ANA, TNF, IL‐6,
•Immune panel (Immunoscience)
Stress and Inflammation
41
Primary Nutritional Support in Sjogren’s
• Sterols/Sterolins
• Phosphorylated serine
• Probiotics
• L‐Glutamine
• IgG Powder
• Cat’s Claw
• DGL licorice
• IgG immune globulin
• MMP modulators 42
8
Additional Support in Sjogren’s
• Assess Heavy metals ‐ use of appropriate detoxification support
• Determine food allergies and sensitivities
• Assess and implement nutrition strategies for neuro‐endocrine‐immune homeostasis
• Address lifestyle factors ‐ diet, exercise, smoking
43
PERVASIVE INFLAMMATION
Gut‐Diabetes Connection
44
Intestinal Microbiome and Diabetes
3 Critical Factors that are now recognized
• Aberrant Intestinal Flora
• “leaky”mucosal barrier
• Altered immune responsiveness
• Vaarala,, O., Atkinson, M, Neu,J The “Perfect Storm for Type 1 Diabetes; Diabetes 2008 October 57(10): 255‐2562
45
Type 1 Diabetes
• Successful management of diabetes requires insulin management, diet, exercise
– Genetics
–T1D risk stratified 100 fold on basis of HLA DR‐DQ genotype
46
Diabetes mellitus
• Islet autoantibodies– High affinity IgG1 class– Over 90% of children w/ T1D have islet autoantibodies– Rarely appear before age 6 months, peaking around 1‐2 yrs
– Antibodies to insulin/proinsulin antigens usually 1st to appear
– Strong association w/HLA‐DR4‐DQ8 w/ pre‐TD1 children
– Immune response thought to occur in Beta cells, particularly ZnT8 cell specific antigen
47
Immunoperoxidase stainings for HLA‐DR (A and B) and HLA‐DP (C and D) in jejunal biopsy specimens from a healthy control (Aand C) and from a type 1 diabetic patient with normal jejunal mucosa (B and D). Intensive, positive HLA‐DR staining is seen throughout the epithelial cells of the villi and also in many crypt cells in the type 2 diabetic specimen (B), whereas the control specimen shows only faint HLA‐DR staining in the apical parts of the epithelial cells at the tip of the villi (A). The biopsy specimen from a control patient treated with HLA‐DP antibody shows scattered positive granules in the apical parts of the epithelial cells at the tip of the villi (C), whereas strong positive staining is seen throughout the villous epithelial cells in the specimen from a type 1 diabetic patient (D). No positive staining is seen with either HLA‐DR or HLA‐DP in crypt cells in the control specimen (A and C). AEC‐hematoxylin stain, original magnification ×50. (Please see http://dx.doi.org/10.2337/db08‐0331 for a high‐quality digital representation of this figure.)
9
Type 1 DiabetesAltered Microbiota
Altered Mucosal Barrier
Diabetes 2008 October 57(10): 255‐2562
49
Microflora
• Infant microbiota important in:
• Growth• Angiogenesis• Nutritional optimization• Help metabolize indigestible compounds, i.e. resistant starches, into energy
• Stimulation of innate and adaptive immunity
Stappenbeck TS, et al. Proc Natl Acad Sci, USA. 2002;99(24):15451‐5.
50
Intestinal Microbiota and T1D
• Important interplay between intestinal microbial environment and intestinal mucosal immunity
• Significant role in autoimmune and metabolic conditions including T1D
• Fermentation of complex carbs by microfloraform energy and involved in pathogenesis of T1D
• i.e. butyrate involved in tight junction formation
Roy CC, et al. Njutr Clin Pract. 2006;21(4):351‐66.51
Intestinal Alterations Observed
• Increased absorption of lactulose and mannitol
• Increased ingested lactulose/mannitol in people with β cell autoimmunity
• Serum zonulin elevation
• Enhanced expression: HLA‐DR/DP, ICAM‐1, integrin, IL4, IL‐1α, IFN‐γ IN in the small intestine
• Increased CD3 and CD 25 w/enhanced ICAM‐1 & HLA‐DR expression sm. Intestine biopsy with gliadin
• Increased expression of matrix metalloproteinases52
Targets
• Maintain Flora
• Tightening of the interepithelial junctions
• Retard propagation of inflammatory and autoimmune signaling pathways via nutritional and pharmacologic means
53
Food
• Milk and Wheat Gliadin both associated with Type 1 diabetes
• Altered wheat Gliadin expressed HLA‐DR and ICAM‐1.
• Vaarala, O., Klemmetti P, et al. Cellular immune response to cow’s milk beta lactaglobulin in patients with newly diagnosed IDDM Diabetes 1996 Feb;45(2):178
• Klemetti, P, Savilahti E, et.al. T‐cell reactivity to wheat gluten in patients with insulin‐dependent diabetes mellitus, Scand J Immunol 1998 Jan;47(1)48‐53
54
10
Intestinal Microbiota and T1D
• Vitamin D important in mucosal integrity and gut permeability
• Microbial imbalances may disable Vitamin D receptor gene expression
• Zipitis CS, et al. Arch Dis Child. 2008;93(6):512‐7.
55
Routine Management of T1DHbA1c
– ADA* • 2‐4 times a year
– NICE** • 2‐6 times a year
Growth (height/weight)‐ ADA
‐ 4 times a year‐ NICE
‐ Every visit
Blood Pressure‐ ADA
– Every physical exam‐ NICE
‐ Every year after age 12
* American Diabetes Association** National Institute for Health and Clinical Excellence 56
57
Biochemical Parameters
• Acetaldehyde hypothesis–fungal metabolism pyruvate produced from sugar by glycolysis
–presence of oxygen prevents formation of acetaldehyde
58
Acetaldehyde Effects on Chemistry• Reduces microtubules in the liver
• Decreases protein secretion, increases retention in the liver
• Engorgement of Golgi apparatus with VLDL
• Accumulation of lipids and proteins, increases hepatocyte size
• Depresses glutathione in Liver Phase II
• Stimulates hepatic smooth endoplasmic reticulum, increases rate of conversion to secondary toxic metabolites
• Increases collagen deposition in the liver
59
Pathways of Formation• Lack of oxygen decarboxylates pyruvate to acetaldehyde and ethanol
• Ethanol conversion by yeast in presence of oxygen and then conversion to acetaldehyde
• Acetaldehyde metabolized in liver and only creates toxicity when high excess formation occurs
• Increases NADH/NAD ratio
• This negatively influences production of ATP60
NADH/NAD Elevated Ratios
• Increases ratio of lactate/pyruvate
• Increases ratio of hydroxysteroids/ ketosteroids
• Decreases galactose tolerance (conversion of galactose to glucose)
• Alters amine metabolism (ie serotonin metabolism)
11
61
NADH/NAD Elevated Ratios• Citric acid cycle changes; inhibition of fatty acid oxidation
– inhibits gluconeogenesis
– amino acids enter for conversion to glycogen, leading to decrease in pyruvate formation, thus increasing deficit of citric acid intermediate oxaloacetate, thereby changing malate/oxaloacetate ratio
• Inhibits glycolysis and ATP production62
NADH/NAD Elevated Ratios
• Elevates blood uric acid levels secondary to increased lactate levels caused by NADH excess; lactate and uric acid compete in tubule for excretion
• Abnormalities in prophyrin metabolism, pooling of coporphyrin
• Inhibits phosphorylation
• Decreases protein synthesis
63
Dysbiosis
Poor Diet Antibiotics Glandular Insufficiency Others
Fungal Overgrowth
General Disturbances
• Absorption Problems
• Bowel Disorders
• Auto‐intoxication
• Digestive Disturbances
– Heartburn/Gas
• Nutrients
– Vitamins B12 and E
– Magnesium
– Copper
– Zinc and Selenium
Allergic Manifestations
• Crohn’s
• Neurodermatitis
• Migraine
• General Unwellness
• Flushing
• Dizziness
• Neuraesthenic
• Toxic
– Fermentation � Alcohol
– Liver burden 64
Key Points onDysbiotic Evolution
• History of tetracycline (or other antibiotics) for 2 months or longer for acne
• History of broad spectrum antibiotics for respiratory, urinary or other infections for a period of 2 months or longer
• Regular exposure to pesticides
• History of prednisone‐type drugs
65
Key Points onDysbiotic Evolution
• Exposure to perfumes, insecticides, fabric odors, and other chemicals causes a reaction
• Damp, muggy days provoke a response
• Persistent athlete’s foot, “jock itch” or infections of the skin and nails
• Cravings for sugar, bread, and alcohol
• Smoke bothers the individual
• History of allergies, asthma, or sinusitis66
DysbiosisA Short List of Primary Symptoms
• Confusion
• Brain fog
• Poor concentration
• Depression
• Aggressive behavior
• Vertigo/dizziness
• Poor learning
• ADD/autism
• Dry mouth, especially during sleep
• Dry eyes
• Blurred vision
• Tinnitus
• Periodontal disease
• Caries
• Sinusitis/allergies
12
67
DysbiosisA Short List of Primary Symptoms
• Respiratory disturbances
• Cardiac arrhythmias/palpitations
• Belching/bloating
• Constipation/diarrhea/colitis/irritable bowel
• Cystitis/urethritis/pruritis
• Eczema
• Menopausal/PMS
• CFS68
Genetics Miasm Birth Trauma
Inadequate Nutrition Nutrient Sparse Toxic
SkewedPoorly
Digested
Toxic Exposure Exotoxin •Air •H20 • Food Dental Fillings Electromagnetic Smoking Medication
Poor EliminationLow Fiber Pulmonary Vent Exercise Poor Water
Accumulated Toxicity (r) + Imbalanced pH
Inactivation of Cellular Function
(Decreased Oxidation)/(Decreased Oxygenation)
�Cancer �Tissue Damage �Endogenic Infection
Tissue Peroxidation
Irreversible Damage
In face of inadequate antioxidant
protective system
< ‐ 371945 ‐ 23Now ‐ 9
ATM PO2
Routine Management of T1DLipid Profile
ADA*
• Adults: at diagnosis then every 1‐2 yr
• Child (low risk): age > 10 yr; then every 1‐5yr
• Child (high risk): after age 2y, then every 1‐5yr
NICE**
• Adult: every year
• Child: not recommended
Foot Examination
‐ ADA *
‐ Every year
‐ ‐ NICE**
‐ Every year
‐ AACE***
‐ Every year
* American Diabetes Association
** National Institute for Health and Clinical Excellence
***American Association of Clinical Endocrinologists 69
Routine Management of T1DNephropathy
– ADA*
• Albumin/Creatinine Ratio
– Every year once diabetes duration > 5yr and age > 10yr
• Serum creatinine
– Every year (adults only)
– NICE**
• Albumin/Creaqtinine Ratio
– Every year after age 12
• Serum creatinine
– Every year from age 12
– AACE***
• Albumin/Creatinine Ratio
– Every year after 5 yr duration
• Serum Creatinine
– Every year after 5 yr duration
* American Diabetes Association
** National Institute for Health and Clinical Excellence
***American Association of Clinical Endocrinologists70
Routine Management of T1DRetinopathy
– ADA*
• Adults: W/in 5 yr of diagnosis, then every yr
• Children: 10yr of age and 3‐5 yr duration, then every year
– NICE**
• Every year from age 12
– AACE***
• Every year after 5 yr duration
Dental Examination
‐ NICE**
‐ Every 2 years
* American Diabetes Association
** National Institute for Health and Clinical Excellence
***American Association of Clinical Endocrinologists 71
Routine Management of T1DNeuropathy
– ADA*
• Distal symmetric polyneuropathy: Every year
• Autonomic Neuropathy: After 5 yr duration
– NICE**
• Adults: Every year
• Children: Not indicated
– AACE***
• Every year after 5 yr duration
* American Diabetes Association
** National Institute for Health and Clinical Excellence
***American Association of Clinical Endocrinologists72
13
Routine Management of T1DThyroid Disease
– ADA*
• TSH; TPO and TG Abs – After metabolic control achieved, then every 1‐2yr; antibodies at diagnosis
– NICE**
• TSH – at diagnosis, then every year
Celiac Disease
‐ ADA*‐ TTG or EMA, IgG and serum IgA – After diagnosis, then periodically
‐ NICE**‐ EMA, IgA and serum IgA – at diagnosis, then every 3 years
* American Diabetes Association
** National Institute for Health and Clinical Excellence73
THYROID & ASSOCIATED TRIAD 2 SHIFTS
Thyroid‐Gut‐Immune Brain Connection
(Triad 1 stacking 2)
74
Thyroid Antibody Formation and the GUT
• Thyroid imbalances and antibody formation are intimately connected to the GUT and the enteric nervous system
75
Thyroid Antibody Formationand the GUT
• Gastrointestinal manifestations of thyroid disease generally due to:
– Reduced motility in hypothyroidism
– Increased motility in hyperthyroidism,
– Autoimmune gastritis, or esophageal compression by a thyroid process
– Symptoms usually resolve with treatment of the thyroid disease.
» Ebert EC. J Clin Gastroenterol. 2010; 76
Thyroid and the Gut
• Celiac cases have 10 times the rate of autoimmune thyroiditis
• Approximately 26%
• Mycotoxins and Molecular mimicry
• Mycotoxins as destructive forces
77
Thyroid Antibody Formation and the GUT – Celiac Disease
• Celiac disease associated with thyroid imbalances• Autoimmune thyroid diseases (AITDs) are most evident.
• Development of AITDs in CD is modulated by:– Genetics – Gluten intake – Selenium deficiency– Environmental factors (i.e. heavy metals, POPs, BPA)
• Leads to overexpression of inflammatory cytokines
– Stazi AV, et al. Ann 1st Super Sanita. 2010;46(4):389‐99. 78
14
Thyroid Antibody Formation and the GUT – Celiac Disease
– Selenoproteins significant in biosyntheis and activity of thyroid hormones.
– Selenoproteins serve as glutathione peroxidases and involved in apoptosis inhibition.
– Selenium malabsorption in CD key factor directly leading to thyroid imbalances and intestinal damage
– Stazi AV, et al. Ann 1st Super Sanita. 2010;46(4):389‐99.
79
Thyroid Antibody Formation and the GUT – Celiac Disease
– Zinc levels important in thyroid hormone balance
– Zinc levels also altered in enteric nervous system imbalances, GI disorders (especially IBD)
– Alkhouri RH, et al. J Pediatr Gastroenterol Nutr.
80
Supplements for Thyroid/GUT • Supplements for autoimmunity and GUT imbalances include:
– Probiotic supplement, 1‐15billion CFU 1‐3 times daily; heat stable
– L‐tyrosine is a precursor to neurotransmitter and thyroid hormone production. Thyroid hormone levels may respond to N‐acetyl‐L‐tyrosine, 250‐500mg daily.
• Thomopoulos P. Rev Prat. 1998;48(18):1987‐91.
– Multiple vitamin, 4‐6 capsules daily
– Zinc carnosine, 1‐2 capsules 14 times daily; helps increase
Mahmood A, et al. Gut. 2007;56:168‐175.
81
Thyroid Stimulating Hormone Receptor
• TSH‐R G protein receptor anchored on the epithelial cells
• TSH binds to site for production of T4
• TSH‐R is the major target of antigen specific T cells
• Antigen specific T cells and autoantigens:
‐ stimulate leading to hyperthyroid state
‐ block leading to hypothyroid state 82
Importance of TSHR
• Deficient expression or blocking of the receptor leads to
‐ reduction in sodium‐iodine symporter(NIS) activity
‐ Reduction in follicles and gland size
‐ Crucial in neonatal development of function and active thyroid tissue
‐ TSHR function in adipocytes and bone cell modulation
83
TSHR • Cysteine rich clusters are necessary for trafficking and confirmation (folding) of receptor
• Leucine is needed in the ectodomain for the binding of TSH
• High affinity TSH binding needs a rich Cysteine environment for disulfide binding
• TSH is highly dependent on Sulfation for receptor activation
• Palmiytolation is critical for cysteine activation, also in lipid disposition
84
15
L CARNITINE 2‐4 GRAMS A DAY REGULATES T3 AND T4 ENTRY INTO THE CELL HELPING TO MODULATE HYPERTHYROID STATE .
Clinical Pearl
85
What disrupts the Thyroid Receptor
• Interference with Transport‐Production and metabolism
• Most Significant: Endocrine Disruptors in 3 ways 1. Mimicry of natural hormones with higher binding
affinity creating stronger or extended signaling or alters timing of signals
2. Bind to the receptor and prevent homoeostatic hormone binding and signaling
3. Inhibition or stimulation of the endocrine receptor then increased or decreased hormone production
86
Top Disruptors of the Thyroid• Humans
• PCB’s
• BPA
• Perchlorate
• Dioxin
• Pentachlorphenol
• Tricolsan
• PBDE (flame retardant)
• Animal
• Phthalates
• DEHP
• DnOP
• DIDP
• DBP
• Resorcinol
Patrick L. Thyroid disruption: mechanism and clinical implications in human health. Altern Med Rev. 2009 Dec;14(4):326‐46. Review. Erratum in: Altern Med Rev. 2010 Apr;15(1):58.Zoeller RT. Environmental chemicals targeting thyroid. Hormones (Athens). 2010 Jan‐Mar;9(1):28‐40. 87
Halogens and Thyroid System Damage
Fluoride in as little as 1 ppm
• Iodinase enzyme damage
• G protein stimulation (affects thyroid hormone uptake into the cell)
• TSH release in inhibited (pituitary)
• Competition for TSHR binding with TSH reducing production
88
Thyroid – Stress ‐ Brain• Type 2 iodothyronine deiodinase (D2) helps control
thyroid signaling• D2 plays central role in T3 content in developing
brain tissue• D2‐catalyzed T3 production increases thyroid
hormone signaling• Blocking D2 activity or disrupting D2 gene leads to
localized hypothyroidism• D2 critical in T4‐mediated negative feedback of
pituitary and hypothalamus• Important in promoting thermogenesis in brown
adipose tissue– Drigo RA, et al. Biochim Biophys Acta. 2012;[Epub ahead of print].
89
Thyroid – Stress ‐ Brain
• Animal studies report high fat diet reported toimbalance D2 signaling
• Leads to hyperactivation of HPA axis• Araujo RL, Endocrinology. 2010;151(7):3460‐9.
• Flaxseed administration reported to helpbalance D1 and D2 activity
• Figuerido MS, et al. Horm Metab Res. 2011;43(6):410‐6.
90
16
Stress and Thyroid Antibodies
• Reduced glucocorticoid activity is associated with an increased prevalence of ThAbspositivity in older ambulatory subjects.
• Terzidis K, et al. Eur J Endocrinol. 2010;162(2):307‐13.
• HPA axis (neuro‐endocrine) imbalances caused by stress‐mediated activation involved in autoimmune thyroid diseases (AITD)
• Klecha AJ, et al. Neuroimmunomodulation. 2008;15(1):68‐75.
91
Stress and Thyroid Autoantibodies
• Increased oxidative stress common in obesity
• Oxidative stress key regulator of TSH levels in pre‐pubertal patients
• In obese children oxidative stress markers reported increased significantly in relation to TSH, independently of BMI‐SDS, age and gender.
» D’Adamo E, et al. Free Radic Res. 2012;46(3):303‐9.
92
Stress and Thyroid Antibodies
• Reduced glucocorticoid activity is associated with an increased prevalence of ThAbspositivity in older ambulatory subjects.
• Terzidis K, et al. Eur J Endocrinol. 2010;162(2):307‐13.
• HPA axis (neuro‐endocrine) imbalances caused by stress‐mediated activation involved in autoimmune thyroid diseases (AITD)
• Klecha AJ, et al. Neuroimmunomodulation. 2008;15(1):68‐75.
93
Thyroid and Brain Development • ↓In thyroid hormone leads to deficiencies in cell migra on in
neocortex, less layering cortical mass, and altered distribution of callosal connections
• Controls differentiation of microglia, dendricytes and astrocytes
• Astrocytes signal uptake of T4 and conversion and delivery of T3 in neurons
• Receptor defects could be significant in behavior TRα1 deficiency can’t forget negative memories, is involved at hippocampus
94
TSH and bone
• TSH has a positive influence on bone remodeling • Inhibits osteoclast • Activates osteoblasts
• Animal models in osteopenia have demonstrated ‐ enhanced trabecular and cortical bone
formation
Abe E, Marians RC, Yu W, et al. Bone loss in thyroid disease: the role of low TSH and High thyroid hormone. Ann N Y Acad Sci 2007;1116:338‐91Bassett JH Williams AJ, MurphyE, et al. A lack of thyoid hormones rather than excess thyrotropin casues abnormal skeletal development in hypothyroidismMol Endocrinol 2008;22:501‐12
95
Vectors and Autoimmune Thyroiditis
• Yersinia enterocolitica (TSH receptor binding sites on its surface)
• Epstein‐Barr Virus‐ causes mononucleosis or “mono.”• Lyme disease spirochete (Borrelia burgdorferi)‐and co
infections (Baesia, erlichia, baronella, mycoplasm)• Rickettsia‐ bacteria transmitted by biting insects.• Hepatitis C – virus that resides in the liver.• Herpes virus – incurable virus found in the nervous system.• Parvovirus B19 – virus that causes “fifths disease” in
children and can affect adults.• Influenza B – The classic “flu” virus.• Rubella – virus that causes German measles.
96
17
VAGAL TONICITY INFLUENCES ON APPETITE AND GUT HORMONE SIGNALING
Adrenal‐Gut Triad 1 stacking 2
97
Gut Hormones in Obesity
• Gut uses an array of humoral factors and vagus nerve stimulation to signal digestion and appetite control
98
Gut Hormones in Obesity
• Pancreatic polypeptide‐fold peptides (PP‐fold)
• Comprised of CNS peptide, neuropeptide Y (NPY), pancreatic polypeptide (PP) and peptide tyrosine‐tyrosine (PYY)
• Important in appetite regulation with distinct roles
99
Gut Hormones in Obesity‐ PYY
• Peptide tyrosine‐tyrosine (PYY)
• PYY co‐released from L cells in GIT w/ glucagon‐like peptide (GLP)‐1 and oxyntomodulin (OXM)
• PYY immunoreactivity highest in rectum
• PYY also distributed in adrenal medulla
• 2 endogenous circulating forms of PYY synthesized in GUT, PYY1‐36 and PYY3‐36
100
Gut Hormones in Obesity ‐ PYY
• PYY secretion important in satiety
• PYY released in circulation in response and proportion to caloric intake
• Humoral factors thought to exist that signal distal portion of GUT to release PYY in response to nutrients in proximal portion
• These include gastrin and cholecystokinin
101
Gut Hormones in Obesity ‐ PYY
• Anorectic conditions characterized by increased circulating PYY3‐36
• Gastric bypass associated with elevated basal and postprandial PYY3‐36
• Peripheral administration of PYY3‐36 reported to inhibit food intake in fasted animals
• Tschop M, et al. Nature. 2004;430:1‐3.
• Acts on hypothalamus as satiety signal and delays gastric emptying
• Disturbances in PYY may play role in obesity102
18
Gut Hormones in Obesity –Pancreatic polypeptide (PP)
• Major stimulus of PP is food ingestion
• Remains elevated 6 hours post food ingestion
• Various humoral factors also found to stimulate PP release (CCK, ghrelin, motilin, secretin)
• Somatostatin reported to inhibit PP release
103
Gut Hormones in Obesity – PP
• Considered part of “ileal brake”
• PP acts to slow transit of food thru GUT
– Delays gastric emptying
– Attenuates pancreatic exocrine secretion
– Inhibits gallbladder contraction• Kojima S, et al. Peptides. 2007;28:459‐63
104
Gut Hormones in Obesity – PP
• Reduces postprandial secretion of PP associated with obesity
• Elevated levels of PP associated with anorexia• Lassman V, et al. Diabetes. 1980;29:428‐30.
• PP may play role in Prader‐Willi syndrome (PWS)
• Patients with PWS have reduced basal and postprandial PP release
105
Gut Hormones in Obesity – PP
• Peripheral injection of PP in animals and humans results in reduced food intake
• PP injection in lean humans resulted in reduced food intake by 25% over 24 hrs
• Batterham RL, et al. J Clin EndocrinolMetab.2004;88:3989‐92.
• Produces anorexia via brainstem and vagusintervention mediated by Y4 receptor
• May also act on hypothalamus and reduced ghrelin release
106
Gut Hormones in Obesity – (GLP)‐1
• Glucagon‐like peptide‐1 (GLP)‐1
• Secreted and released by L cells of intestine
• GLP‐17‐36amide is major form in circulation
• T1/2 of GLP‐1 is only 2 minutes in blood
• Thought to be component of “ileal brake”
– Plays role in metabolism of ingested carbs
– Inhibits gastric acid secretion
– Delays gastric emptying107
Gut Hormones in Obesity – (GLP)‐1
• Also up‐regulates various stages of insulin production
• Significant weight loss reported in animals administered GLP‐1
• Meeran K, et al. Endocrinology 1999;140:244‐50.
• Dose dependent reduction in caloric intake and appetite reduction in humans reported in lean, obese and diabetic individuals
• Naslund E, et al. Br J Nutr. 2004;91:439‐46.
• However, rapid degradation makes unsuitable for obesity tx
108
19
Gut Hormones in Obesity – (GLP)‐1
• Exendin‐4 developed as a long‐acting analog of GLP‐1
• FDA approved exenatide in 2004 as 1st incretin‐mimetic agent
• Used as adjunctive Tx in T2DM• Lowers fasting glycemia, postprandial glycemia dn HbA1c
• Meta‐analysis reports exenatide reduces weight by av. Of 1.44kg compared to placebo and 4.76kg compared to insulin
• Amori RE, et al. J Am Med Assoc. 2007;298;194‐206.109
Gut Hormones in Obesity – GLP‐1
• Exenatide SE’s include increased nausea, vomiting, diarrhea compared to placebo or insulin
• SEs mild to moderate during 1st 8wks of therapy, with decreased effects during dose titration
110
Gut Hormones in Obesity – GLP‐1
• Liraglutide also GLP‐1 analog bound to albumin
• Administered SQ
• Studies report weight loss of 1.2kg and decreased HbA1c after 12 wks of SQ injection QD
• Similar SEs to exenatide
• Used in Tx of T2DM 111
Gut Hormones in Obesity – GLP‐1
• GLP‐1 half‐life also increased by altering DPP‐IV enzyme
• Oral antagonists include sitagliptin and vildagliptin
• However meta analysis reports increased weight gain and altered lipid profile (decreased HDL) when compared to placebo
• Amori RE, et al. J Am Med Assoc. 2007;298;194‐206.
112
Gut Hormones in Obesity – OXM
• Oxyntomodulin (OXM)
• 37 amino peptide that displays glucagon‐like activity in liver
• Has entire sequence of glucagon with addition of octapeptide C‐terminal extension (spacerpeptide‐1)
• Co‐released w/ GLP‐1 and PYY from L cells
• Binds to GLP‐1 receptor 113
Gut Hormones in Obesity – OXM
• OXM possess incretin activity but stimulates insulin release much less than GLP‐1
• Functions as satiety hormone
• Released in circulation following food ingestion and levels reflect caloric intake
– Inhibitor or pentagastrin‐induced gastric acid secretion
– Delays gastric emptying114
20
Gut Hormones in Obesity – OXM
• OXM levels increased after gastric bypass
• Nutrients diverted away from stomach and proximal sm. intestines to regions of high OXM expression (distal sm. Intestines and colon)
• Reports that OXM plays essential role in wt. loss after gastric bypass
• Holst JJ, et al. Scand J Gastroenterol. 1979;14:205‐7.
115
Gut Hormones in Obesity – OXM
• OXM injection results in appetite suppression and weight loss
• Injection in animals resulted in similar potency of GLP‐1 in re: to food intake
• Dakin CL, et al. Endocrinology. 2004;145:2687‐95.
• May lead to weight reduction by increased energy expenditure
• Reported to decrease release of ghrelin in lab animals
116
Gut Hormones in Obesity – OXM
• OXM in humans reported to improve satiety
• Healthy, fasting volunteers experienced significant reduction in hunger and plasma ghrelin levels compared to placebo
• Also reduced energy intake (19.3%) postinfusion when compared to placebo and remained low 12hr post injection
• Cohen MA, et al. J Clin Endocrinol Metab. 2003;88:3989‐92. 117
Gut Hormones in Obesity – OXM
• OXM potency comparable to GLP‐1, although receptor binding is 2 orders of magnitude less than GLP‐17‐36amide
• Fehmann HC, et al. Peptides.1994;15:453‐6.
118
Gut Hormones in Obesity – Ghrelin
• Growth hormone secretagogues (GHS) include (GH)‐releasing peptide‐6 and hexarelin
• GHS‐receptor (GHR‐R) binds and mediates effects of GH secretagogues
• Ghrelin identified as ligand that binds to GHR‐R• Kojima M, et al. Nature. 1999;51(Suppl 3):1‐8.
• GHR‐R expressed in hypothalamus, GIT, myocardium, pituitary, pancreas, adipose tissue, liver, kidney and placenta
119
Gut Hormones in Obesity – Ghrelin
• Ghrelin principally excreted from X/A‐like cells in gastric oxyntic glands
• Gastrectomy reported to decrease ghrelin content by 80%
• Date Y, et al. Endocrinology. 2000;141:4255‐61.
• Remainder of ghrelin secreted from intestine, pancreas, pituitary and colon
120
21
Gut Hormones in Obesity – Ghrelin
• Ghrelin – Stimulates appetite
– Only gut hormone that stimulates food intake
– Increases gastric motility
– Up‐regulates hypothalamo‐pituitary‐adrenal axis
– Cardiac effects including vasodilation, increased cardiac contractility
• Ghrelin also acts as neurotransmitter ‐expressed w/in hypothalamus
121
Gut Hormones in Obesity – Ghrelin
• Plasma levels of ghrelin correlate inversely with body weight
• Levels significantly higher in lean individuals vs. obese
• Diet‐induced weight loss increases circulating ghrelin levels
• Increases preprandially and decreases postprandially in lean humans and animals
• Hosoda H, et al. J Pharm Sci. 2006;100:398‐410.
122
Gut Hormones in Obesity – Ghrelin
• Food intake fails to suppress plasma ghrelin levels in obese individuals
• Dysregulation of ghrelin thought to play role in obesity
• Circulating levels of ghrelin decreased in gastric bypass
• 28% increase in energy consumption reported during buffet meal
• May help in cachexiaWren AM, et al. J Clin Endocrinol Metab. 2001;86:5992‐5.
123
Gut Hormones in Obesity – CKK• Cholecystokinin (CKK)
• 1st gut hormone implicated in appetite regulation
• Peptide hormone expressed in sm. Intestine
• Released rapidly in response to food intake
• CKK:
– stimulates pancreatic and gallbladder exocrine secretions
– Inhibits gastric emptying
– Increases intestinal motility
• Also expressed as neurotransmitter
– Involved in reward behavior
– Anxiety
– Memory• Little TJ, et al. Obes Rev. 2005;6:297‐306.
• CKK infusion reported to fail to have effect on food intake beyond 24hr• Kissileff HR, et al. Am J Physiol Regul Integr Comp Physiol. 2003;285:R992‐8.
124
Summary
• Primary concern is to correct immune shift in the gut causing systemic neuro‐endocrine‐immune shifts
• Rebuild nutrient pools
• Reestablish cross‐talk communication between hormones with appropriate negative feedback loops.
125